Increased serum levels of anti-angiogenic factors soluble fms-like tyrosine kinase and soluble endoglin in sickle cell disease.
The anti-angiogenic factors soluble fms-like tyrosine kinase (sFlt)-1 and soluble endoglin (sEng) have been shown to be of importance in angiogenesis by sequestering and inhibiting vascular endothelial growth factor, placenta-like growth factor and transforming growth factor-beta(1) signaling. Given the potential role of angiogenesis in the pathophysiology of sickle cell disease (SCD)-related complications, serum levels of sFlt-1 and sEng were determined in SCD patients and controls. Both sFlt-1 (p = 0.002) and sEng (p = 0.004) were elevated in patients during clinically asymptomatic SCD with no further increment during painful crisis. These data suggest that sFlt-1 and sEng may be important in the regulation of angiogenesis in SCD.
Landburg
P P
PP
Immunology Laboratory Department, Red Cross Blood Bank Foundation, Curaçao, Netherlands Antilles.
Elsenga
H
H
Schnog
J B
JB
Duits
A J
AJ
D000755:Anemia, Sickle Cell / Q000097:blood* / Q000503:physiopathology; D020533:Angiogenesis Inhibitors / Q000097:blood*; D015703:Antigens, CD / Q000097:blood*; D000071063:Endoglin; D005260:Female; D006801:Humans; D008297:Male; D009389:Neovascularization, Pathologic / Q000097:blood* / Q000503:physiopathology; D011956:Receptors, Cell Surface / Q000097:blood*; D015398:Signal Transduction; D053773:Transforming Growth Factor beta1 / Q000097:blood; D042461:Vascular Endothelial Growth Factor A / Q000097:blood; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000097:blood*
D020533:Angiogenesis Inhibitors; D015703:Antigens, CD; C064206:ENG protein, human; D000071063:Endoglin; D011956:Receptors, Cell Surface; D053773:Transforming Growth Factor beta1; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C501162:FLT1 protein, human; D040281:Vascular Endothelial Growth Factor Receptor-1